MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
Quantitative Magnetic Resonance Spectroscopic Imaging (MRSI) to Predict Early Response to Standard Radiation Therapy (RT)/Temozolomide (TMZ) ± Belinostat Therapy in Newly-Diagnosed Glioblastomas (GBM)
Sponsor: Emory University
A PHASE2 clinical study on Glioblastoma Multiforme of Brain, this trial is ongoing. The trial is conducted by Emory University and has accumulated 14 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Jun 2025 — Present [monthly]
Unknown PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Jun 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2021 — Jun 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 9 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Mar 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE2
-
Aug 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2018 — Aug 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Oct 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Emory University
- Johns Hopkins University
- National Cancer Institute (NCI)
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health (NIH)
- Spectrum Pharmaceuticals, Inc
For direct contact, visit the study record on ClinicalTrials.gov .